About Nexus Oncology
Nexus Oncology is a company based in Edinburgh (United Kingdom) founded in 1999 was acquired by Chiltern in January 2012. Nexus Oncology offers products and services including Roundtable Discussions, Video Clips, and Conferences. Nexus Oncology operates in a competitive market with competitors including Helsinn, Aster Insights, CancerVax, Oncotherapeutics and Abogen Biosciences, among others.
- Headquarter Edinburgh, United Kingdom
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nexus Oncology
Nexus Oncology offers a comprehensive portfolio of products and services, including Roundtable Discussions, Video Clips, and Conferences.
Connects experts with oncologists for clinical data updates.
Delivers short videos on latest clinical data via text messages.
Hosts events for advancing oncology knowledge and practices.
Funding Insights of Nexus Oncology
Detailed funding history for Nexus Oncology
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Nexus Oncology
Nexus Oncology has secured backing from 1 investor. Prominent investors backing the company include Chiltern.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Full-service oncology CRO operations are conducted globally.
|
Locked | Locked | Locked |
Investor details for Nexus Oncology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nexus Oncology
Investment portfolio details for Nexus Oncology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nexus Oncology
Detailed financials for Nexus Oncology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nexus Oncology Comparisons
Peer comparison for Nexus Oncology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nexus Oncology
Nexus Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Helsinn, Aster Insights, CancerVax, Oncotherapeutics and Abogen Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Oncology therapeutics are developed, manufactured, and commercialized by Helsinn.
|
|
| Locked | Locked | Locked |
Contract-based oncology clinical trial services are provided by Aster Insights.
|
|
| Locked | Locked | Locked |
Cancer vaccine research and development is conducted by CancerVax.
|
|
| Locked | Locked | Locked |
Preclinical and clinical oncology drug development services are provided.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics are developed for cancer and infectious diseases.
|
|
| Locked | Locked | Locked |
CRO offering clinical development services for oncology drugs
|
Detailed competitors of Nexus Oncology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nexus Oncology
Complete news archive for Nexus Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nexus Oncology
Nexus Oncology was founded in 1999.
Nexus Oncology is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Nexus Oncology was founded in 1999 in Edinburgh, United Kingdom, as a contract research organization focused on the oncology sector. Clinical research services were delivered to biopharmaceutical companies for the development of cancer treatments. Drug development programs were designed and implemented across phase I, II, and III oncology trials. The company was acquired by Ockham in February 2012.
Nexus Oncology offers Roundtable Discussions, Video Clips, and Conferences.
Nexus Oncology has 1 investor. Key investors include Chiltern.